1. Swerdlow SH, Berger F, Pikeru SA. Lymphoplasmacytic lymphoma. In : Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumour of hematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press;2007. p. 194–195.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30:110–115. PMID:
12720118.
Article
3. Issa GC, Leblebjian H, Roccaro AM, Ghobrial IM. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol. 2011; 18:260–265. PMID:
21519243.
Article
4. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood. 2007; 109:5096–5103. PMID:
17303694.
Article
5. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009; 23:153–161. PMID:
18818699.
Article
6. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381:1203–1210. PMID:
23433739.
Article
7. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013; 31:301–307. PMID:
23233721.
Article
9. Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24:vi155–vi159. PMID:
24078658.
10. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014; 124:1404–1411. PMID:
25027391.
Article
11. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015; 126:721–732. PMID:
26002963.
Article
12. Ioakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009; 9:62–66. PMID:
19362976.
Article
13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235–242. PMID:
11807147.
Article
14. Nobile-Orazio E, Marmiroli P, Baldini L, et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology. 1987; 37:1506–1514. PMID:
2442666.
Article
15. Nemni R, Gerosa E, Piccolo G, Merlini G. Neuropathies associated with monoclonal gammapathies. Haematologica. 1994; 79:557–566. PMID:
7503840.
16. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009; 113:4163–4170. PMID:
19196866.
17. Treon SP, Merlini G, Morra E, Patterson CJ, Stone MJ. Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011; 11:69–73.
Article
18. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23:3–9. PMID:
18971951.
Article
20. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002; 20:2327–2333. PMID:
11981004.
Article
21. Gertz MA, Abonour R, Heffner LT, Greipp PR, Uno H, Rajkumar SV. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol. 2009; 147:677–680. PMID:
19751237.
Article
22. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26:4579–4586. PMID:
18662969.
Article
23. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106:3725–3732. PMID:
16123223.
Article
24. Buske C, Sadullah S, Kastritis E, et al. Generation of a large observational pan-European data platform for treatment and outcome patterns in patients with Waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2015; 126(Suppl):abst 2096.
Article
25. Olszewski AJ, Fallah J, Eaton CB, Treon SP, Castillo JJ. The evolution of management and survival outcomes of Waldenström macroglobulinemia (WM) in the United States (US). Blood (ASH Annual Meeting Abstracts). 2015; 126(Suppl):abst 882.
Article
26. Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenström macroglobulinemia: a population-based analysis. Oncologist. 2016; 21:1377–1386.
Article
27. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007; 25:3344–3349. PMID:
17577016.
Article
28. Kikuchi M, Nakasone H, Akahoshi Y, et al. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma. J Chemother. 2015; 27:99–105. PMID:
25314911.
Article
29. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011; 12:460–468. PMID:
21482186.
30. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013; 122:3276–3282. PMID:
24004667.